Voyager Therapeutics, Inc.
voyagertherapeutics.comWhat Do They Do?
Develops gene therapies, antibodies and small-molecule treatments for neurological diseases, advancing programs with pharmaceutical and biotechnology partners.
10-K for FY2025, filed Mar 9, 2026We are a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure…View ↗
We are advancing our own proprietary pipeline of drug candidates for neurological diseases, with a focus on AD. Our wholly-owned…View ↗
In addition to our wholly-owned pipeline, we are advancing three programs with collaboration partners for which we retain options to…View ↗
Our third opt-in program is our collaboration with Transition Bio to develop selective small molecules for the treatment of amyotrophic…View ↗
How Do They Make Money?
Partners pay upfront and option fees, reimburse research costs, make development or regulatory milestone payments, and pay royalties on licensed product sales. Research costs are reimbursed as the work proceeds, and royalties are tied to related sales.
10-K for FY2025, filed Mar 9, 2026The Company enters into license, option, and collaboration agreements which are within the scope of ASC Topic 606, Revenue from Contracts…View ↗
The Company’s contracts often include development and regulatory milestone payments that are assessed under the most likely amount method…View ↗
For arrangements that include sales-based royalties, including milestone payments based on the level of sales, in which the license is…View ↗
Upfront payments and fees are recorded as contract liabilities within deferred revenue on the consolidated balance sheets until the Company…View ↗
$40.4M
-
10-K for FY2025, filed Mar 9, 2026
$40.4M ↗
Who Are Their Customers?
Pharmaceutical and biotechnology partners license Voyager’s capsids or product candidates and collaborate on research and development programs.
10-K for FY2025, filed Mar 9, 2026We are a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure…View ↗
We are collaborating with Neurocrine on three gene therapy programs against undisclosed targets. Two of these three programs have…View ↗
The Company enters into license, option, and collaboration agreements which are within the scope of ASC Topic 606, Revenue from Contracts…View ↗
Do Revenues Turn Into Profits?
No. It lost $119.7M in FY2025.
10-K for FY2025, filed Mar 9, 2026
−$131.8MView ↗
10-K for FY2025, filed Mar 9, 2026
−$119.7MView ↗
10-K for FY2025, filed Mar 9, 2026
−$135.1MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 6, 2026
−$24.5MView ↗
- ▼ −27% (Loss)
- vs −$33.4M in Q2 FY2025
-
Apr 21, 2026
CFO Nathan Jorgensen resigns
His resignation took effect May 8, 2026; Robin Swartz was appointed principal financial officer and treasurer.
Sources
8-K, filed Apr 21, 2026
On April 15, 2026, Nathan Jorgensen, Ph.D. notified Voyager Therapeutics, Inc. (the “Company”) of his decision to resign from his position…View ↗
Flat. Revenue was $40.4M in FY2025, about the same as the $37.4M of FY2021.
Proprietary pipeline focus
Earlier, the wholly owned pipeline included a gene-therapy program for ALS and an anti-tau antibody for Alzheimer’s; the latest report centers on tau-targeted Alzheimer’s programs, including gene therapy and an antibody.
10-K for FY2022, filed Mar 7, 2023 10-K for FY2025, filed Mar 9, 2026In addition to leveraging TRACER capsids in potential licensing arrangements, we are advancing our own proprietary pipeline of drug…View ↗
We are advancing our own proprietary pipeline of drug candidates for neurological diseases, with a focus on AD. Our wholly-owned…View ↗
Added delivery approach
The earlier business description centered on AAV gene therapy and TRACER capsid discovery; the latest also describes Voyager NeuroShuttle, a non-viral platform for moving neurotherapeutics across the blood-brain barrier.
10-K for FY2022, filed Mar 7, 2023 10-K for FY2025, filed Mar 9, 2026We are identifying proprietary AAV capsids, the outer viral protein shells that enclose genetic material that makes up the vector payload.…View ↗
We have leveraged our knowledge of BBB receptors, discovered using TRACER, to develop a second delivery platform called Voyager…View ↗
Who Do They Compete With?
Competes with Lundbeck, Merck &, Teijin, Eisai, Janssen Pharmaceuticals, Johnson & Johnson, UCB, Bristol-Myers Squibb, Prothena, Ionis Pharmaceuticals, Biogen, Dewpoint Therapeutics, WaveBreak Therapeutics, Molefy Pharma, 4D Molecular Therapeutics, Affinia Therapeutics, Apertura Gene Therapy, Capsida Biotherapeutics, Capsigen, and Dyno Therapeutics
10-K for FY2025, filed Mar 9, 2026Our anti-tau antibody program for AD will potentially compete with tau antibodies being developed by Lundbeck LLC, Merck & Co., Inc. in…View ↗
Loading...
